199 Biotechnologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

199 Biotechnologies is an early-stage, private biotech firm developing a novel platform targeting epigenetic damage as the root cause of both cancer and aging. Its core strategy involves three synergistic programs: a lead cancer reprogramming therapy for glioblastoma (E-ON-001), a senolytic compound research program with a lead candidate (Procyanidin C1), and an affordable diagnostic service called AgeQuant. The company aims to transform treatment paradigms from destructive to restorative, offering potentially less toxic and more durable interventions for age-related diseases.

OncologyLongevity/AgingNeurological Disorders

Technology Platform

Integrated 'Rewrite, Clear, Measure' platform. 'Rewrite' uses partial epigenetic reprogramming (e.g., Yamanaka factors) to restore youthful cellular function or modify cancer cell behavior. 'Clear' involves discovery of senolytic compounds (e.g., Procyanidin C1) to eliminate senescent cells. 'Measure' is the AgeQuant diagnostic platform for affordable biomarker testing.

Opportunities

The company operates in the massive and growing longevity and oncology markets, with a first-in-class approach targeting epigenetic reprogramming.

Its commercial AgeQuant diagnostics and planned senolytic supplement provide early revenue streams and valuable real-world biomarker data, de-risking the business model while the core therapeutic program advances.

Risk Factors

The core scientific premise of safe, controlled partial reprogramming in vivo is highly novel and unproven, carrying significant technical risk.

As a preclinical company with a multifaceted strategy, it faces execution and substantial funding challenges.

The regulatory path for an epigenetic reprogramming cancer therapy is undefined and could be lengthy.

Competitive Landscape

In reprogramming, it faces early-stage competitors like Altos Labs and Life Biosciences, but with a distinct focus on oncology. In senolytics, it competes with Unity Biotechnology and numerous nutraceutical companies. Its AgeQuant platform competes with traditional diagnostic labs and direct-to-consumer testing companies like InsideTracker, competing on price and speed.

More companies in Regenerative Medicine →More companies in United Kingdom →